What happened with INVA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
GSK pays Innoviva royalties tied to global net sales of the inhaled respiratory medicines RELVAR/BREO ELLIPTA and ANORO ELLIPTA. These payments provide most of Innoviva’s revenue, with RELVAR/BREO contributing the larger share. Innoviva holds contractual rights to this income, but GSK controls development, manufacturing, marketing and sales. That makes GSK’s commercial performance central to Innoviva’s business, without Innoviva controlling the sales effort.
Innoviva also sells critical-care and infectious-disease medicines to healthcare systems through Innoviva Specialty Therapeutics. GIAPREZA, which raises blood pressure in adults with septic or other distributive shock, and XACDURO, which treats certain hospital-acquired bacterial pneumonias, account for most product sales. The company also holds exclusive U.S. marketing rights to Basilea’s antibiotic ZEVTERA. This business depends on hospitals adopting its medicines and outside manufacturers maintaining supply; promotion is limited to approved uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Innoviva’s respiratory royalties face competition from privately held Boehringer Ingelheim’s Spiriva and Stiolto, while its growing hospital drug portfolio depends on Basilea for ZEVTERA supply.
GSK sells BREO/RELVAR and ANORO respiratory inhalers and pays Innoviva royalties on those sales, generating $250.3 million in gross royalties in 2025. Watch these inhalers’ sales and pricing rather than GSK’s overall growth: Innoviva attributed its 2025 net royalty decline mainly to lower sales driven by U.S. pricing pressures.
Zai Lab buys XACDURO exclusively from Innoviva for its medicine business in Greater China, making it a direct customer of Innoviva’s antibiotic portfolio. Its interim supply agreement drove most of Innoviva’s $40.9 million in XACDURO sales outside the United States in 2025, but those supplies were billed at cost.
Innoviva owns 68.8% of Armata Pharmaceuticals, Inc. and finances its development of bacteria-targeting viruses, or bacteriophages, to treat difficult bacterial infections. Watch Armata’s funding needs and AP-SA02 clinical development: its 2025 revenue came from MTEC covering a share of that program’s clinical costs, rather than drug sales.
AstraZeneca’s Symbicort and Bevespi compete for asthma and COPD prescriptions with GSK’s inhalers, whose sales pay Innoviva royalties. Watch sales of these competing inhalers for pressure on BREO/RELVAR and ANORO, rather than treating AstraZeneca’s broader drug sales as a signal for Innoviva.
GSK plc earningsGSK
GSK's report will show how sales and pricing for BREO/RELVAR and ANORO shape Innoviva's royalty income.
Watch BREO/RELVAR and ANORO sales and pricing, not GSK's overall growth. Steady sales and easing price pressure on the inhalers would support Innoviva's royalties; falling sales or heavier U.S. price pressure would mean continued strain on this major income source.
Innoviva, Inc. earningsThis company
Innoviva's report will show whether sales of its medicines can offset pressure on GSK royalties and support operating income.
Read product sales alongside royalties from GSK, then check whether operating income holds up. Rising product sales with royalties stabilizing would show Innoviva's medicines are widening its revenue base without the inhaler royalty stream shrinking further; weaker product sales and falling royalties would show both engines under pressure, making operating income harder to sustain.
